PARP1 and neoplasm: For instance, mutated patients potentially benefit from PARP inhibitors such as Olaparib, rucaparib, niraparib and telazoparib [1,18], through a mechanism of synthetic lethality, causing selective tumor cell cytotoxicity in cell lines.